Applied Therapeutics, Inc. (NASDAQ:APLT) Shares Bought by Barclays PLC

Barclays PLC increased its position in Applied Therapeutics, Inc. (NASDAQ:APLT) by 186.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 200,012 shares of the company’s stock after acquiring an additional 130,102 shares during the period. Barclays PLC’s holdings in Applied Therapeutics were worth $1,702,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in the business. Janus Henderson Group PLC increased its holdings in Applied Therapeutics by 37.8% in the third quarter. Janus Henderson Group PLC now owns 10,541,528 shares of the company’s stock valued at $89,656,000 after buying an additional 2,893,323 shares in the last quarter. State Street Corp lifted its stake in shares of Applied Therapeutics by 123.1% in the third quarter. State Street Corp now owns 3,694,607 shares of the company’s stock worth $31,404,000 after buying an additional 2,038,724 shares in the last quarter. Frazier Life Sciences Management L.P. boosted its position in Applied Therapeutics by 17.1% during the second quarter. Frazier Life Sciences Management L.P. now owns 2,286,135 shares of the company’s stock worth $10,676,000 after acquiring an additional 333,278 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Applied Therapeutics by 165.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 735,217 shares of the company’s stock valued at $6,249,000 after purchasing an additional 457,940 shares during the last quarter. Finally, Ally Bridge Group NY LLC acquired a new position in shares of Applied Therapeutics during the 3rd quarter valued at about $5,256,000. 98.31% of the stock is owned by hedge funds and other institutional investors.

Applied Therapeutics Trading Down 3.8 %

Shares of NASDAQ:APLT opened at $0.85 on Friday. The company has a market cap of $99.29 million, a PE ratio of -0.53 and a beta of 1.76. The company’s 50 day moving average is $5.83 and its two-hundred day moving average is $5.99. Applied Therapeutics, Inc. has a 52 week low of $0.77 and a 52 week high of $10.62.

Analyst Upgrades and Downgrades

A number of research firms have commented on APLT. Royal Bank of Canada reduced their target price on Applied Therapeutics from $4.00 to $1.50 and set a “sector perform” rating on the stock in a research report on Friday, December 20th. Robert W. Baird lowered their target price on Applied Therapeutics from $14.00 to $5.00 and set an “outperform” rating for the company in a report on Friday, November 29th. UBS Group reiterated a “neutral” rating and set a $2.00 price target (down from $13.00) on shares of Applied Therapeutics in a research note on Monday, December 2nd. William Blair downgraded shares of Applied Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, December 23rd. Finally, Leerink Partners increased their target price on shares of Applied Therapeutics from $11.00 to $14.00 and gave the stock an “outperform” rating in a report on Thursday, September 19th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $6.10.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.